NovoCure Ltd Quarterly Cost of Revenue in USD from Q3 2014 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
NovoCure Ltd quarterly/annual Cost of Revenue history and growth rate from Q3 2014 to Q3 2024.
  • NovoCure Ltd Cost of Revenue for the quarter ending September 30, 2024 was $35.4M, a 10.2% increase year-over-year.
  • NovoCure Ltd Cost of Revenue for the twelve months ending September 30, 2024 was $136M, a 9.36% increase year-over-year.
  • NovoCure Ltd annual Cost of Revenue for 2023 was $128M, a 11.7% increase from 2022.
  • NovoCure Ltd annual Cost of Revenue for 2022 was $115M, a 0.01% decline from 2021.
  • NovoCure Ltd annual Cost of Revenue for 2021 was $115M, a 7.87% increase from 2020.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $136M $35.4M +$3.28M +10.2% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-30
Q2 2024 $133M $34.7M +$636K +1.87% Apr 1, 2024 Jun 30, 2024 10-Q 2024-07-25
Q1 2024 $132M $33.7M +$4.08M +13.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q4 2023 $128M $32.6M +$3.67M +12.7% Oct 1, 2023 Dec 31, 2023 10-Q 2024-10-30
Q3 2023 $125M $32.1M +$2.34M +7.88% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-30
Q2 2023 $122M $34M +$5.52M +19.3% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-25
Q1 2023 $117M $29.6M +$1.89M +6.81% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q4 2022 $115M $28.9M -$799K -2.69% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-22
Q3 2022 $116M $29.7M -$457K -1.51% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-26
Q2 2022 $116M $28.5M -$96K -0.34% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-27
Q1 2022 $116M $27.7M +$1.34M +5.09% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $115M $29.7M +$1.55M +5.51% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-22
Q3 2021 $113M $30.2M +$1.81M +6.38% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $112M $28.6M +$3.13M +12.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-28
Q1 2021 $108M $26.4M +$1.89M +7.71% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-28
Q4 2020 $107M $28.1M +$3.35M +13.5% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-23
Q3 2020 $103M $28.4M +$5.5M +24% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $97.7M $25.5M +$4.37M +20.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 $93.3M $24.5M +$4.68M +23.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-29
Q4 2019 $88.6M $24.8M +$1.76M +7.63% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-24
Q3 2019 $86.8M $22.9M +$3.95M +20.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-29
Q2 2019 $82.9M $21.1M +$1.27M +6.42% Apr 1, 2019 Jun 30, 2019 10-Q/A 2020-10-02
Q1 2019 $81.6M $19.8M +$1.58M +8.64% Jan 1, 2019 Mar 31, 2019 10-Q/A 2020-10-02
Q4 2018 $80M $23M +$7.39M +47.2% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-25
Q3 2018 $72.7M $18.9M +$3.8M +25.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-10-31
Q2 2018 $68.9M $19.8M +$6.68M +50.8% Apr 1, 2018 Jun 30, 2018 10-Q 2019-07-25
Q1 2018 $62.2M $18.2M +$6.57M +56.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $55.6M $15.6M +$4.67M +42.5% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-27
Q3 2017 $50.9M $15.2M +$4.04M +36.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-10-25
Q2 2017 $46.9M $13.2M +$3.36M +34.2% Apr 1, 2017 Jun 30, 2017 10-Q 2018-07-26
Q1 2017 $43.6M $11.7M +$3.68M +46.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-26
Q4 2016 $39.9M $11M +$4.67M +74.1% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-28
Q3 2016 $35.2M $11.1M +$5.46M +96.5% Jul 1, 2016 Sep 30, 2016 10-Q 2017-10-26
Q2 2016 $29.7M $9.8M +$5.05M +106% Apr 1, 2016 Jun 30, 2016 10-Q 2017-07-27
Q1 2016 $24.7M $7.98M +$4.09M +105% Jan 1, 2016 Mar 31, 2016 10-Q 2017-04-27
Q4 2015 $20.6M $6.3M Oct 1, 2015 Dec 31, 2015 10-K 2018-02-22
Q3 2015 $5.66M +$3.07M +119% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-02
Q2 2015 $4.75M Apr 1, 2015 Jun 30, 2015 10-Q 2016-07-28
Q1 2015 $3.9M Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-10
Q3 2014 $2.59M Jul 1, 2014 Sep 30, 2014 10-Q 2015-10-27
* An asterisk sign (*) next to the value indicates that the value is likely invalid.